Adaptive Biotechnologies (NASDAQ:ADPT) CFO Kyle Piskel Sells 3,115 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 3,115 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the transaction, the chief financial officer owned 256,725 shares in the company, valued at $3,347,694. The trade was a 1.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total value of $245,910.24.

Adaptive Biotechnologies Trading Up 7.7%

ADPT stock traded up $1.00 during midday trading on Wednesday, reaching $13.96. The stock had a trading volume of 1,918,799 shares, compared to its average volume of 1,623,319. The company’s fifty day simple moving average is $13.81 and its 200 day simple moving average is $15.65. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -42.30 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 52-week low of $8.50 and a 52-week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.20) EPS. Sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on ADPT shares. JPMorgan Chase & Co. reduced their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Morgan Stanley reduced their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, Guggenheim reiterated a “buy” rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of ADPT. AQR Capital Management LLC raised its holdings in Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the period. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies in the 1st quarter valued at about $93,000. New York State Common Retirement Fund raised its holdings in Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after buying an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after buying an additional 333,379 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.